C. Weiss

发表

Cross-Neutralizing Antibodies to Pandemic 2009 H1N1 and Recent Seasonal H1N1 Influenza A Strains Influenced by a Mutation in Hemagglutinin Subunit 2

Dorothy Scott, Min Zhuang, Hong Yang, 2011, PLoS pathogens.

A mutation in the receptor binding site enhances infectivity of 2009 H1N1 influenza hemagglutinin pseudotypes without changing antigenicity.

J. Castelán-Vega, Alicia Jiménez-Alberto, Wei Wang, 2010, Virology.

Characterization of lentiviral pseudotypes with influenza H5N1 hemagglutinin and their performance in neutralization assays.

Hang Xie, Wei Wang, R. Vassell, 2010, Journal of virological methods.

Establishment of retroviral pseudotypes with influenza hemagglutinins from H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing antibodies.

Wei Wang, R. Vassell, Z. Ye, 2008, Journal of virological methods.

HIV-1 gp41 Residues Modulate CD4-Induced Conformational Changes in the Envelope Glycoprotein and Evolution of a Relaxed Conformation of gp120

R. Vassell, C. Weiss, P. Keller, 2018, Journal of Virology.

Trimeric, Coiled-coil Extension on Peptide Fusion Inhibitor of HIV-1 Influences Selection of Resistance Pathways*

Wei Wang, Christopher J. De Feo, M. Zhuang, 2012, The Journal of Biological Chemistry.

Antibodies to Antigenic Site A of Influenza H7 Hemagglutinin Provide Protection against H7N9 Challenge

Wei Wang, C. Weiss, J. Weir, 2015, PloS one.

Selection with a Peptide Fusion Inhibitor Corresponding to the First Heptad Repeat of HIV-1 gp41 Identifies Two Genetic Pathways Conferring Cross-Resistance to Peptide Fusion Inhibitors Corresponding to the First and Second Heptad Repeats (HR1 and HR2) of gp41

Wei Wang, Christopher J. De Feo, M. Zhuang, 2011, Journal of Virology.

Generation of a protective murine monoclonal antibody against the stem of influenza hemagglutinins from group 1 viruses and identification of resistance mutations against it

Esmeralda Alvarado-Facundo, Wei Wang, R. Vassell, 2019, PloS one.

Glycosylation of Residue 141 of Subtype H7 Influenza A Hemagglutinin (HA) Affects HA-Pseudovirus Infectivity and Sensitivity to Site A Neutralizing Antibodies

Esmeralda Alvarado-Facundo, Wei Wang, R. Vassell, 2016, PloS one.

Neutralizing Antibody Responses to Homologous and Heterologous H1 and H3 Influenza A Strains After Vaccination With Inactivated Trivalent Influenza Vaccine Vary With Age and Prior-year Vaccination.

L. Katzelnick, Wei Wang, R. Vassell, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Serum Samples From Middle-aged Adults Vaccinated Annually with Seasonal Influenza Vaccines Cross-neutralize Some Potential Pandemic Influenza Viruses

D. Scott, Esmeralda Alvarado-Facundo, Wei Wang, 2015, The Journal of infectious diseases.

Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting.

B. Walker, D. Kuritzkes, J. Martinez-Picado, 2019, The lancet. HIV.

Thiol/disulfide exchange is a prerequisite for CXCR4-tropic HIV-1 envelope-mediated T-cell fusion during viral entry.

C. Broder, C. Weiss, K. Strebel, 2004, Blood.

Peptides Corresponding to the Heptad Repeat Motifs in the Transmembrane Protein (gp41) of Human Immunodeficiency Virus Type 1 Elicit Antibodies to Receptor-Activated Conformations of the Envelope Glycoprotein

P. Wingfield, R. Vassell, C. Weiss, 2001, Journal of Virology.

Characterization of stable Chinese hamster ovary cells expressing wild-type, secreted, and glycosylphosphatidylinositol-anchored human immunodeficiency virus type 1 envelope glycoprotein

J. White, C. Weiss, Carol D. Weiss, 1993, Journal of virology.

Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants

Wei Wang, R. Vassell, C. Weiss, 2022, Journal of virology.

Characterization of entry pathways, species-specific ACE2 residues determining entry, and antibody neutralization evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 variants

Wei Wang, R. Vassell, C. Weiss, 2022, bioRxiv.

SARS-CoV-2 antibodies remain detectable 12 months after infection and antibody magnitude is associated with age and COVID-19 severity

C. Broder, R. Vassell, C. Weiss, 2021, medRxiv.

Durability of antibody responses and frequency of clinical and subclinical SARS-CoV-2 infection six months after BNT162b2 COVID-19 vaccination in healthcare workers

W. Wang, C. Broder, R. Vassell, 2021, medRxiv.

Controversies: the role of HIV specialists.

C. Weiss, P. Gillette, A. Strelnick, 1998, JAMA.

Identification and preliminary characterization of vaccinia virus (Dryvax) antigens recognized by vaccinia immune globulin.

C. Weiss, M. Merchlinsky, J. Weir, 2005, Virology.

Resistance to N-peptide fusion inhibitors correlates with thermodynamic stability of the gp41 six-helix bundle but not HIV entry kinetics

Wei Wang, Christopher J. De Feo, M. Zhuang, 2014, Retrovirology.

Determination of influenza B identity and potency in quadrivalent inactivated influenza vaccines using lineage-specific monoclonal antibodies

Esmeralda Alvarado-Facundo, Wei Wang, C. Weiss, 2017, PloS one.

Post-vaccination Omicron infections induce broader immunity across antigenic space than prototype mRNA COVID-19 booster vaccination or primary infection

Rupal M Mody, C. Broder, B. Agan, 2022, bioRxiv.

Surveillance Study of Influenza Occurrence and Immunity in a Wisconsin Cohort During the 2009 Pandemic

C. Viboud, M. Eichelberger, J. Gorski, 2017, Open forum infectious diseases.

The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants

A. Gruber, B. Bosch, H. Binz, 2022, Nature biotechnology.

Recombinant A27 protein synergizes with modified vaccinia Ankara in conferring protection against a lethal vaccinia virus challenge.

R. Vassell, C. Weiss, M. Merchlinsky, 2010, Vaccine.

SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster

Rupal M Mody, C. Broder, B. Agan, 2021, bioRxiv.

Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine--induced immunity.

I. Berkower, J. Manischewitz, H. Golding, 2007, The Journal of infectious diseases.

Defining the risk of SARS-CoV-2 variants on immune protection

Larissa B. Thackray, Vineet D. Menachery, Thomas P. Fabrizio, 2022, Nature.

Antigenic cartography of well-characterized human sera shows SARS-CoV-2 neutralization differences based on infection and vaccination history

C. Broder, B. Agan, L. Katzelnick, 2022, Cell Host & Microbe.

WHO collaborative study to assess the suitability of an interim standard for antibodies to Ebola virus

E. Postnikova, R. Tedder, W. Hogrefe, 2016 .

Resistance to N-peptide fusion inhibitors correlates with thermodynamic stability of the gp41 six-helix bundle but not HIV entry kinetics

Wei Wang, Christopher J. De Feo, M. Zhuang, 2014, Retrovirology.

Studies of HIV‐1 envelope glycoprotein‐mediated fusion using a simple fluorescence assay

D. Littman, N. Killeen, J. White, 1996, AIDS.

Triazine Dyes Inhibit HIV‐1 Entry by Binding to Envelope Glycoproteins

Shigemichi Nishikawa, C. Weiss, T. Uchiyama, 1997, Microbiology and immunology.

Capture of an early fusion-active conformation of HIV-1 gp41

C. Weiss, C. Wild, R. Furuta, 1998, Nature Structural Biology.

Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects

A. Eakin, Wei Wang, R. Vassell, 2021, bioRxiv.

D-dimer and CoV-2 spike-immune complexes contribute to the production of PGE2 and proinflammatory cytokines in monocytes

Yun-Jong Park, S. Khurana, H. Golding, 2022, PLoS pathogens.

The human immunodeficiency virus and the adrenal medulla.

C. Weiss, 1986, Annals of internal medicine.

Optimal conditions for recovery of the human immunodeficiency virus from peripheral blood mononuclear cells

J. Levy, C. Weiss, L. Wiviott, 1988, Journal of clinical microbiology.

Isolates of human immunodeficiency virus type 1 from the brain may constitute a special group of the AIDS virus.

C. Cheng‐Mayer, J. Levy, C. Weiss, 1989, Proceedings of the National Academy of Sciences of the United States of America.

Oligomeric organization of gp120 on infectious human immunodeficiency virus type 1 particles

J. Levy, J. White, C. Weiss, 1990, Journal of virology.

Multispecific DARPin® therapeutics demonstrate very high potency against SARS-CoV-2 variants in vitro

M. Stumpp, A. Bosshart, F. Malvezzi, 2021 .

Structure-Function Studies of the Self-Assembly Domain of the Human Immunodeficiency Virus Type 1 Transmembrane Protein gp41

C. Weiss, Yongkai Weng, Zhongning Yang, 2000, Journal of Virology.

Escape from Human Immunodeficiency Virus Type 1 (HIV-1) Entry Inhibitors

Christopher J. De Feo, C. Weiss, 2012, Viruses.

Human Immunodeficiency Virus (HIV) gp41 Escape Mutants: Cross-Resistance to Peptide Inhibitors of HIV Fusion and Altered Receptor Activation of gp120

Yong He, Paul Wingfield, P. Wingfield, 2005, Journal of Virology.

Peptides Trap the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Fusion Intermediate at Two Sites

Nga Nguyen, Yong He, R. Vassell, 2003, Journal of Virology.

Bivalent COVID-19 vaccine antibody responses to Omicron variants suggest that responses to divergent variants would be improved with matched vaccine antigens

Wei Wang, R. Vassell, C. Weiss, 2023, medRxiv.

Inhibitors that target fusion

C. Weiss, Wang Wei, 2007 .

Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2

Wei Wang, R. Vassell, C. Weiss, 2020, bioRxiv.

Influenza Virus M2 Protein Ion Channel Activity Helps To Maintain Pandemic 2009 H1N1 Virus Hemagglutinin Fusion Competence during Transport to the Cell Surface

Yamei Gao, Alicia Jiménez-Alberto, Esmeralda Alvarado-Facundo, 2014, Journal of Virology.

HIV-1 gp41: mediator of fusion and target for inhibition.

C. Weiss, 2003, AIDS reviews.

SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity

L. Katzelnick, A. Eakin, Wei Wang, 2021, Viruses.

SARS-COV-2 Delta variant displays moderate resistance to neutralizing antibodies and spike protein properties of higher soluble ACE2 sensitivity, enhanced cleavage and fusogenic activity

L. Katzelnick, A. Eakin, Wei Wang, 2021, bioRxiv.

SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum, but evades most convalescent serum and therapeutic antibodies

C. Broder, B. Agan, L. Katzelnick, 2022, Science Translational Medicine.

Durability of Antibody Response and Frequency of SARS-CoV-2 Infection 6 Months after COVID-19 Vaccination in Healthcare Workers

C. Broder, R. Vassell, C. Weiss, 2022, Emerging infectious diseases.

NIAID recommendations for treating HIV infection.

C. Weiss, 1994, Journal of the American Medical Association (JAMA).

Neutralizing and protective epitopes of the 2009 pandemic influenza H1N1 hemagglutinin

Hang Xie, Wei Wang, Z. Ye, 2012, Influenza and other respiratory viruses.

Neutralizing Antibodies Targeting the Conserved Stem Region of Influenza Hemagglutinin

R. Vassell, C. Weiss, Sabari Nath Neerukonda, 2020, Vaccines.

Conformational Stability of the Hemagglutinin of H5N1 Influenza A Viruses Influences Susceptibility to Broadly Neutralizing Stem Antibodies

Esmeralda Alvarado-Facundo, Wei Wang, R. Vassell, 2018, Journal of Virology.

Intermonomer Interactions in Hemagglutinin Subunits HA1 and HA2 Affecting Hemagglutinin Stability and Influenza Virus Infectivity

Esmeralda Alvarado-Facundo, Wei Wang, R. Vassell, 2015, Journal of Virology.

Mutational Analysis of Residues in the Coiled-Coil Domain of Human Immunodeficiency Virus Type 1 Transmembrane Protein gp41

C. Weiss, Yongkai Weng, 1998, Journal of Virology.

Comparison of A(H3N2) neutralizing antibody responses elicited by 2018-2019 season quadrivalent influenza vaccines derived from eggs, cells, and recombinant hemagglutinin.

M. Eichelberger, A. Ganesan, Esmeralda Alvarado-Facundo, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Neutralizing and Neuraminidase Antibodies Correlate With Protection Against Influenza During a Late Season A/H3N2 Outbreak Among Unvaccinated Military Recruits

M. Eichelberger, Angelia A. Eick-Cost, R. Forshee, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Comparison of hemagglutination inhibition and hemagglutinin pseudovirus neutralization titres in relation to protection against influenza in a mouse model

R. Forshee, Hang Xie, Wei Wang, 2021, Letters in applied microbiology.

Immunogenicity and Protection Against Influenza H7N3 in Mice by Modified Vaccinia Virus Ankara Vectors Expressing Influenza Virus Hemagglutinin or Neuraminidase

M. Eichelberger, Jin Gao, Wei Wang, 2018, Scientific Reports.

Neutralizing and protective murine monoclonal antibodies to the hemagglutinin of influenza H5 clades 2.3.2.1 and 2.3.4.4

Wei Wang, C. Weiss, J. Weir, 2023, Influenza and other respiratory viruses.

Immunogens Modeling a Fusion-Intermediate Conformation of gp41 Elicit Antibodies to the Membrane Proximal External Region of the HIV Envelope Glycoprotein

D. Montefiori, C. Labranche, I. Srivastava, 2015, PloS one.

Capture of an early fusion-active conformation of HIV-1 gp41

C. Weiss, C. Wild, R. Furuta, 1998, Nature Structural Biology.

Binding of the 2F5 Monoclonal Antibody to Native and Fusion-Intermediate Forms of Human Immunodeficiency Virus Type 1 gp41: Implications for Fusion-Inducing Conformational Changes

Shibo Jiang, R. Kunert, R. Vassell, 2004, Journal of Virology.

Dissection of Human Immunodeficiency Virus Type 1 Entry with Neutralizing Antibodies to gp41 Fusion Intermediates

S. Zolla-Pazner, M. Gorny, D. Dimitrov, 2002, Journal of Virology.

An external quality assessment feasibility study; cross laboratory comparison of haemagglutination inhibition assay and microneutralization assay performance for seasonal influenza serology testing: A FLUCOP study

R. Webby, Shinji Watanabe, L. Carolan, 2023, Frontiers in Immunology.

Optimal Conditions forRecovery oftheHumanImmunodeficiency Virus fromPeripheral BloodMononuclear Cells

J. Levy, C. Weiss, L. Wiviott, 1988 .

In Praise of Imperfection: My Life and Work

C. Weiss, 1988 .

D614G and Omicron SARS-CoV-2 variant spike proteins differ in the effects of N-glycan modifications on spike expression, virus infectivity, and neutralization by some therapeutic antibodies

Wei Wang, R. Vassell, C. Weiss, 2023, bioRxiv.

Influenza Virus M2 Protein Ion Channel Activity Helps To Maintain Pandemic 2009 H1N1 Virus Hemagglutinin Fusion Competence during Transport to the Cell Surface

Yamei Gao, Alicia Jiménez-Alberto, Esmeralda Alvarado-Facundo, 2014, Journal of Virology.

Envelope-mediated T-cell Fusion during Viral Entry Thiol/disulfide Exchange Is a Pre-requisite for Cxcr4-tropic Hiv-1

C. Broder, C. Weiss, K. Strebel, 2022 .